Figure 3.
Forest plot displaying the meta-analysis of progression free survival.
Notes: (A) BEV/taxane-based triplet therapy versus BEV/taxane doublet therapy; (B) BEV/taxane therapy with the addition of a cytotoxic agent versus BEV/taxane doublet therapy; (C) BEV/taxane therapy with the addition of a biologic agent versus BEV/taxane doublet therapy.
Abbreviations: BEV, bevacizumab; HR, hazard ratio; SE, standard error; IV, inverse variance; CI, confidence interval.